Mirae Asset Global Investments Co. Ltd. Increases Holdings in Sanofi (NASDAQ:SNY)

Mirae Asset Global Investments Co. Ltd. raised its stake in Sanofi (NASDAQ:SNY) by 5.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,350 shares of the company’s stock after purchasing an additional 2,464 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Sanofi were worth $2,305,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership raised its holdings in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock valued at $172,611,000 after buying an additional 2,468,271 shares during the period. Morgan Stanley raised its stake in shares of Sanofi by 19.3% during the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after purchasing an additional 1,251,199 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Sanofi during the first quarter worth $41,800,000. Envestnet Asset Management Inc. boosted its stake in shares of Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after purchasing an additional 651,756 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Sanofi by 24.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 2,643,615 shares of the company’s stock valued at $132,260,000 after purchasing an additional 515,245 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Stock Performance

Sanofi stock opened at $45.39 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a fifty day moving average price of $47.52 and a two-hundred day moving average price of $48.67. The company has a market cap of $114.82 billion, a PE ratio of 19.23, a P/E/G ratio of 1.71 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 12.56% and a return on equity of 27.47%. Research analysts expect that Sanofi will post 4.16 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.